2015
DOI: 10.1200/jco.2015.33.15_suppl.1529
|View full text |Cite
|
Sign up to set email alerts
|

Personalized Genomic Analyses for Cancer Mutation Discovery and Interpretation.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…Our workforce requirements model takes this dynamic into account through Pathway 6 ( Figure 1 ), which in the base case assumes that 11.5% of new cancer patients receive tumour testing and P/LP germline mutations are detected in 3% of those patients, which leads to Pathway 6 only accounting for about 1% of the caseload and <1% of FTE requirements. However, while the 11.5% tumour testing rate was calculated based on comprehensive country-wide data from France [ 24 ], it reflects practice as of 2017, and the 3% germline variant estimate is from 2015 [ 25 ]. If either statistic increases by 2030 (which appears likely based on more recent studies [ 23 ]), the impact of germline P/LP variants detected through somatic testing on overall hereditary cancer clinics’ workforce requirements could increase significantly.…”
Section: Discussionmentioning
confidence: 99%
“…Our workforce requirements model takes this dynamic into account through Pathway 6 ( Figure 1 ), which in the base case assumes that 11.5% of new cancer patients receive tumour testing and P/LP germline mutations are detected in 3% of those patients, which leads to Pathway 6 only accounting for about 1% of the caseload and <1% of FTE requirements. However, while the 11.5% tumour testing rate was calculated based on comprehensive country-wide data from France [ 24 ], it reflects practice as of 2017, and the 3% germline variant estimate is from 2015 [ 25 ]. If either statistic increases by 2030 (which appears likely based on more recent studies [ 23 ]), the impact of germline P/LP variants detected through somatic testing on overall hereditary cancer clinics’ workforce requirements could increase significantly.…”
Section: Discussionmentioning
confidence: 99%